Winthrop Advisory Group LLC Invests $234,000 in Novo Nordisk A/S (NYSE:NVO)

Winthrop Advisory Group LLC acquired a new stake in Novo Nordisk A/S (NYSE:NVO) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 1,968 shares of the company’s stock, valued at approximately $234,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Lewis Asset Management LLC increased its holdings in shares of Novo Nordisk A/S by 3.4% during the third quarter. Lewis Asset Management LLC now owns 5,472 shares of the company’s stock valued at $652,000 after purchasing an additional 182 shares during the period. Channel Wealth LLC increased its stake in Novo Nordisk A/S by 15.6% during the 3rd quarter. Channel Wealth LLC now owns 57,353 shares of the company’s stock valued at $6,829,000 after buying an additional 7,756 shares during the period. Portside Wealth Group LLC raised its position in shares of Novo Nordisk A/S by 3.9% during the 3rd quarter. Portside Wealth Group LLC now owns 59,015 shares of the company’s stock worth $7,027,000 after buying an additional 2,200 shares in the last quarter. Consolidated Planning Corp lifted its stake in shares of Novo Nordisk A/S by 1.9% in the 3rd quarter. Consolidated Planning Corp now owns 55,134 shares of the company’s stock worth $6,565,000 after acquiring an additional 1,038 shares during the period. Finally, Keudell Morrison Wealth Management boosted its holdings in shares of Novo Nordisk A/S by 5.8% in the third quarter. Keudell Morrison Wealth Management now owns 8,170 shares of the company’s stock valued at $973,000 after acquiring an additional 451 shares in the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. StockNews.com upgraded Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. BMO Capital Markets decreased their target price on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a research note on Thursday, October 17th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Novo Nordisk A/S has an average rating of “Buy” and a consensus target price of $144.50.

Novo Nordisk A/S Trading Up 2.1 %

Shares of NYSE NVO opened at $107.62 on Friday. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.46. Novo Nordisk A/S has a 12 month low of $94.73 and a 12 month high of $148.15. The company has a market cap of $482.95 billion, a price-to-earnings ratio of 36.86, a P/E/G ratio of 1.43 and a beta of 0.42. The business has a fifty day simple moving average of $122.65 and a 200-day simple moving average of $130.59.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Wednesday, August 7th. The company reported $0.65 EPS for the quarter, missing the consensus estimate of $0.71 by ($0.06). Novo Nordisk A/S had a net margin of 34.86% and a return on equity of 87.43%. The firm had revenue of $9.82 billion during the quarter, compared to analysts’ expectations of $9.91 billion. Sell-side analysts predict that Novo Nordisk A/S will post 3.01 EPS for the current year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.